Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genotonorm for Growth Retardation in Children
NCT00163215Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jan 2005
- Primary completion
- Oct 2011
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of somatropin, sponsored by Pfizer. Primary endpoints: Change From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA) at 36 months and Change From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA) in Per-Protocol Population at 36 months. Started Jan 2005; status: completed.
02
Drugs
somatropin
Beyond the preview
Go deeper on NCT00163215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00163215.